RegeneRx Biopharmaceuticals, Inc. (RGRX)

0.0014 0.0000 (0.00%) As of 01:15PM EDT. Market open.

RegeneRx Biopharmaceuticals, Inc.

15245 Shady Grove Road
Suite 470
Rockville, MD 20850
United States
301 208 9191
https://www.regenerx.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 2

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Allan L. Goldstein Ph.D.	Founder, Chairman, Chief Scientific Officer & Chairman of Scientific Advisor Board	86.54k	N/A	1938
Mr. J. J. Finkelstein	President, CEO & Director	75.26k	N/A	1952

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair, and regeneration. The company is developing RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology; RGN-352, an injectable formulation for the treatment of cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications; and RGN-137, a topical gel for the treatment of dermal wounds and reduction of scar tissue. It has strategic partnerships with Lee's Pharmaceutical Group and HLB Therapeutics. The company was formerly known as Alpha 1 Biomedicals, Inc. and changed its name to RegeneRx Biopharmaceuticals, Inc. in 2000. RegeneRx Biopharmaceuticals, Inc. was incorporated in 1982 and is based in Rockville, Maryland.

Corporate governance

RegeneRx Biopharmaceuticals, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.